Atlas Trials

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Clinical trial NCT03245151 · COMPLETED

Trial details

NCT number
NCT03245151
Sponsor
Eisai Inc.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Recurrent and Refractory Solid Tumors
Start date
2017-11-16
Primary completion
2022-09-30
Enrollment
64

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.